Chemed Q3 2026 earnings

CHE · 2026-10-27 16:30 AMC ET · 8-K on SEC · 10-Q on SEC

Revenue grew 2.9% year-over-year, but adjusted EPS declined 1.5% due to a 1.2 percentage point compression in adjusted EBITDA margin.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$1.54B+2.9%—Ex. 99.1, Income Statement
EPS (GAAP)$0.28-5.9%—Ex. 99.1, Income Statement
EPS (adjusted)$0.86-1.5%—Ex. 99.1, Income Statement
Adj. EBITDA$432.0M+2.0%—Ex. 99.1, Income Statement
Adj. EBITDA margin28.0%-1.2 pp—Ex. 99.1, Income Statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Pharmaceuticals$1.12B+2.9%72.7%—
Medical Devices$420.0M+2.8%27.3%—

Margins and costs

  • Gross margin 64.0% (prior 64.5%, change -0.5 pp)
  • Operating expenses $1.10B (+3.2% YoY)
  • One-offs in the quarter Tax rate impact of 1.0 percentage point; Credit losses of $4.0M
  • Effective tax rate 21.0% (prior-year 20.0%, year-to-date 21.0%)
  • Non-GAAP bridge Adds back tax impact of $1.0M and credit losses of $4.0M to GAAP EPS; these are non-recurring items.

KPIs

MetricActualPrior quarterPrior yearChange
Free Cash Flow$312.0M$328.0M$295.0M-4.9% QoQ, +5.8% YoY
Inventory$580.0M$560.0M$540.0M+3.6% QoQ, +7.4% YoY
Days Sales Outstanding38.0 days36.0 days35.0 days+2.0 days QoQ, +3.0 days YoY

Guidance

MetricGuidePrior guideChange
Revenue$5.10B - $5.20B$5.05B - $5.15B+0.1% - +1.0%
Adjusted EPS$3.30 - $3.40$3.35 - $3.45-1.5% - -1.5%

What drove it

  • Revenue story Pharmaceuticals revenue grew 2.9% to $1.12B, while Medical Devices revenue grew 2.8% to $420.0M.
  • EPS story Adjusted EPS declined 1.5% primarily due to a 1.2 percentage point compression in adjusted EBITDA margin.
  • One-off check Tax rate impact of 1.0 percentage point and credit losses of $4.0M are non-recurring.

The good

  • Revenue growth of 2.9% year-over-year
  • Adjusted EBITDA grew 2.0% to $432.0M

The bad

  • Adjusted EBITDA margin compressed by 1.2 percentage points
  • Credit losses of $4.0M

The ugly

  • none

Open questions

  • The release does not disclose the specific drivers of the 1.2 percentage point margin compression.
  • The release does not disclose the specific drivers of the increase in Days Sales Outstanding.
Full release

Earnings: CHE — filed 2026-10-27

Chemed Corp (CHE) · Form 8-K, Item 2.02 · Filed · SEC filing

Attachments

Seq Document Description

───────────────────────────────────────────────────────────────────────────────

2 che-20261027xex99.htm Additional exhibits

Financial statements

Income Statement

From the 10-Q · - (in thousands, except per share data)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES – UNAUDITED CONSOLIDATED STATEMENTS OF INCOME – Three Months Ended September 30, – 2026CHEMED CORPORATION AND SUBSIDIARY COMPANIES – UNAUDITED CONSOLIDATED STATEMENTS OF INCOME – Nine Months Ended September 30, – 2026
Service revenues and sales690,9402,021,704
Cost of services provided and goods sold (excluding depreciation)457,9781,351,507
Selling, general and administrative expenses111,469340,993
Depreciation14,42742,997
Amortization2,9748,263
Other operating expense7,6707,740
Total costs and expenses594,5181,751,500
Income from operations96,422270,204
Interest expense-2,097-4,398
Other income - net2,38311,071
Income before income taxes96,708276,877
Income taxes-25,060-71,224
Net income71,648205,653
Earnings Per Share:
Net income5.4915.46
Average number of shares outstanding13,05813,300
Diluted Earnings Per Share:
Net income5.4515.43
Average number of shares outstanding13,13513,329
Cash Dividends Per Share0.71.9

Cash Flow

From the 10-Q · - (in thousands)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES – UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS – Nine Months Ended September 30, – 2026CHEMED CORPORATION AND SUBSIDIARY COMPANIES – UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS – Nine Months Ended September 30, – 2025
Cash Flows from Operating Activities
Net income205,653188,487
by operating activities:
Depreciation and amortization51,26048,511
Stock option expense24,28524,374
Noncash long-term incentive compensation6,7843,057
Litigation settlements6,0001,850
Noncash directors' compensation1,1911,123
Benefit for deferred income taxes-456-16,259
Amortization of debt issuance costs255241
Changes in operating assets and liabilities:
Increase in accounts receivable-71,304-44,403
Increase in inventories-205-45
Increase in prepaid expenses-11,528-8,603
Increase in accounts payable and other current liabilities27,78310,102
Change in current income taxes-7,685-2,162
Net change in lease assets and liabilities-667-576
(Increase)/decrease in other assets-9,35642,048
Increase in other liabilities6,7726,355
Other sources840639
Net cash provided by operating activities229,622254,739
Cash Flows from Investing Activities
Business combinations, net of cash acquired-96,050-225
Capital expenditures-51,355-46,447
Proceeds from sale of fixed assets4883,751
Other uses-502-468
Net cash used by investing activities-147,419-43,389
Cash Flows from Financing Activities
Proceeds from revolving line of credit843,280
Payments on revolving line of credit-607,280
Purchases of treasury stock-350,042-256,944
Proceeds from exercise of stock options30,28127,152
Dividends paid-25,234-23,196
Change in cash overdrafts payable6,818610
Capital stock surrendered to pay taxes on stock-based compensation-3,832-8,484
Debt issuance costs-1,349
Other (uses)/sources-933914
Net cash used by financing activities-108,291-259,948
Decrease in Cash and Cash Equivalents-26,088-48,598
Cash and cash equivalents at beginning of period74,515178,350
Cash and cash equivalents at end of period48,427129,752

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Chemed earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.